Results 21 to 30 of about 8,269 (200)

Prognostic value of a new clinically-based classification system in patients with CMML undergoing allogeneic HCT: a retrospective analysis of the EBMT-CMWP [PDF]

open access: yes, 2022
Recently a new three-group clinical classification was reported by an International Consortium to stratify CMML patients with regard to prognosis. The groups were defined as follows: (1) Myelodysplastic (MD)-CMML: WBC ≤ 10 × 109/l, circulating immature ...
Schouten H. C.   +26 more
core   +2 more sources

Heightened NLRP3 inflammasome activation is associated with aging and CMML diseases severity [PDF]

open access: yes, 2022
Aging causes chronic low-grade inflammation known as inflamm-aging. It is a risk factor for chronic myelomonocytic leukemia (CMML), a hematological malignancy that is most prevalent in older people.
Ansermet, Camille   +19 more
core   +3 more sources

CMML is in the eye of the be-WHO-lder: interrogating the newly proposed entity of oligomonocytic CMML: MDS or CMML? [PDF]

open access: yesBlood Neoplasia
The World Health Organization and international consensus 2022 classifications have proposed lowering the absolute monocyte count threshold to ≥ 0.5 × 109/L for the diagnosis of chronic myelomonocytic leukemia (CMML). This was based on reports describing patients with oligomonocytic CMML (O-CMML) (0.5 × 109/L to 1.0 × 109/L) as a CMML variant.
Komrokji RS   +12 more
europepmc   +3 more sources

Prognostic impact of the bone marrow tumor microenvironment, HLA-I and HLA-Ib expression in MDS and CMML progression to sAML [PDF]

open access: yesOncoImmunology
Genetic aberrations and immune escape are fundamental in MDS and CMML initiation and progression to sAML. Therefore, quantitative and spatial immune cell organization, expression of immune checkpoints (ICP), classical human leukocyte antigen class I (HLA-
Marcus Bauer   +9 more
doaj   +2 more sources

Outcomes of intermediate or high‐risk CMML patients treated with hypomethylating agents combined with venetoclax: A single center experience

open access: yesClinical and Translational Science
Chronic myelomonocytic leukemia (CMML) treatment remains a pressing clinical challenge. We conducted a retrospective analysis on 52 CMML cases, exploring the effectiveness of combining venetoclax (Vene) with hypomethylating agents (HMAs).
Chao Li   +10 more
doaj   +2 more sources

CSF3R T618I mutated chronic myelomonocytic leukemia: A proliferative subtype with a distinct mutational profile

open access: yesLeukemia Research Reports, 2022
Chronic myelomonocytic leukemia (CMML) is a clonal myeloid neoplasm characterized by sustained monocytosis and mutations in TET2, ASXL1, SRSF2, SETBP1, NRAS, and KRAS. We describe a rare case of CSF3R T618I mutated CMML that has a proliferative phenotype,
Adelaide Kwon   +6 more
doaj   +1 more source

Chronic myelomonocytic leukemia in the light of the WHO proposals

open access: yesHaematologica, 2007
The WHO classification moved CMML to myeloproliferative/myelodysplastic disorders, and defined CMML I and CMML II according to medullary and peripheral blast count.
Ulrich Germing   +9 more
doaj   +1 more source

Case Report: CMML in Young Age which Transformed to AML

open access: yesClinical and Research Journal in Internal Medicine, 2023
CMML (Chronic Myelomonocytic Leukemia) is a rare type of blood cancer that characterized with the presents of monocytes in the blood. 1,2 According to WHO it is categorized as overlapped manifestation of MDS (Myelodysplastic Syndrome) and MPD ...
Wilujeng Anggraini, Herwindo Brahmantyo
doaj   +1 more source

Chronic myelomonocytic leukaemia stem cell transcriptomes anticipate disease morphology and outcome

open access: yesEBioMedicine, 2020
Background: Chronic myelomonocytic leukaemia (CMML) is a clinically heterogeneous stem cell malignancy with overlapping features of myelodysplasia and myeloproliferation. Over 90% of patients carry mutations in epigenetic and/or splicing genes, typically
Daniel H Wiseman   +6 more
doaj   +1 more source

Home - About - Disclaimer - Privacy